Mankind Pharma shares gained 1% on December 18 after acquiring a 1.29% stake in Actimed Therapeutics for £999,900.
Post-acquisition, Mankind Pharma holds 10.19% of Actimed Therapeutics shares. The investment focuses on the treatment of cancer cachexia, amyotrophic lateral sclerosis, and muscle-wasting disorders.
At the time of writing, Mankind Pharma shares were quoted at Rs 1,940.55 apiece on the BSE, up 2.50% from the previous session’s close.
On December 12, Chrys Capital sold Rs 3,282 crore worth of Mankind Pharma shares in a block deal. The shares were offloaded through Chrys Capital’s subsidiary Beige Ltd, totaling 1.79 crore shares.
Nuvama Alternative & Quantitative Research anticipates a significant increase in Mankind Pharma’s free float post the mega stake sale.
The company’s Rs 4,326-crore IPO in April was one of the largest by a domestic pharma player since 2020. Mankind Pharma had a strong debut on the bourses in May, listing at a 20% premium to its IPO price.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
